ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors

Recruiting now · Phase 1/Phase 2

Conditions studied: HR+/HER2- Breast Cancer, HR+, HER2-, Advanced Breast Cancer

In brief

This study, the first clinical trial of AVZO-023, aims to determine the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, maximum tolerated dose, and anti-tumor effects of AVZO-023 in patients with advanced solid tumors. AVZO-023 is an oral medication that inhibits cyclin-dependent kinase 4 (CDK4).

Key facts

Study ID
NCT06998407
Run by
Avenzo Therapeutics, Inc.
People needed
380
Starts
2025-08-20
Expected to finish
2030-08-01
Last updated by the study team
2026-07-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.